CliffBio
biologic

Nulojix

belatacept

Loss of exclusivityJune 2023projected — 12-year biologic exclusivity estimate
CompanyBristol-Myers Squibb Company →See this company's full patent-cliff portfolio

Drug detail

Brand nameNulojix
Active ingredientbelatacept
Strength250MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalJune 2011
Marketing statusRx

More from Bristol-Myers Squibb Company

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Nulojix patent cliff — loss of exclusivity June 2023 | CliffBio